April 19, 2024
Bio
Genexine to begin clinical trials of HyLeukin-7
[THE INVESTOR] Genexine and its US affiliate NeoImmuneTech said on Oct. 30 that the US Food and Drug Administration has approved its Investigational New Drug application for clinical trials of its treatment of newly diagnosed high-grade glioma patients with a combination of HyLeukin-7 and standard therapy.
The drug candidate that is being co-developed by the two companies is an immunotherapeutic treatment designed to induce T cell proliferation and helps the body fight serious disease.
“The new trials will study the effect of HyLeukin-7, an innovative immunotherapeutic agent, on lymphocyte counts and disease progression in patients with brain cancer following chemotherapy and radiation. HyLeukin-7 is expected to increase the T cell count and provide clinical benefits to patients with brain cancer whose prognosis is poor with conventional therapy alone,” said NgocDiep Le, NeoImmuneTech’s chief medical officer.
“Many patients with high-grade gliomas can have a severe reduction in immune cells that can be associated with reduced survival rate, making this treatment particularly relevant for HGG. The safety and efficacy of different doses of this new agent will be also explored.”
The study will enroll up to 46 patients and will be conducted in collaboration with the Washington University School of Medicine, led by Principal Investigator Jian Campian.
By Park Han-na (hnpark@heraldcorp.com)
The drug candidate that is being co-developed by the two companies is an immunotherapeutic treatment designed to induce T cell proliferation and helps the body fight serious disease.
“The new trials will study the effect of HyLeukin-7, an innovative immunotherapeutic agent, on lymphocyte counts and disease progression in patients with brain cancer following chemotherapy and radiation. HyLeukin-7 is expected to increase the T cell count and provide clinical benefits to patients with brain cancer whose prognosis is poor with conventional therapy alone,” said NgocDiep Le, NeoImmuneTech’s chief medical officer.
“Many patients with high-grade gliomas can have a severe reduction in immune cells that can be associated with reduced survival rate, making this treatment particularly relevant for HGG. The safety and efficacy of different doses of this new agent will be also explored.”
The study will enroll up to 46 patients and will be conducted in collaboration with the Washington University School of Medicine, led by Principal Investigator Jian Campian.
By Park Han-na (hnpark@heraldcorp.com)
